Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet?

Pfizer has acquired Metsera for $4.9 billion, strategically bolstering its GLP-1 pipeline with investigational oral and less frequent dosing weight management therapies to target the rapidly expanding market, projected to reach $150 billion by 2035. This move aims to secure a niche against leaders like Eli Lilly and Novo Nordisk, and is viewed as part of a broader positive outlook for Pfizer, supported by improving Q2 financial results (10% revenue, 30% adjusted EPS growth), a robust and diverse pipeline, recent approvals, cost efficiencies, and an attractive valuation of 7.7x forward earnings compared to the industry average.

Analysis

Pfizer is executing a strategic entry into the high-growth GLP-1 weight management market through the $4.9 billion cash acquisition of Metsera. This transaction provides Pfizer with a portfolio of differentiated assets, including a Phase 2 GLP-1 candidate (MET-097i) being tested for both weekly and monthly dosing, and two pre-clinical oral therapies. These candidates address key unmet needs for less frequent and non-injectable treatments, positioning Pfizer to capture a niche in a market projected to grow from $15 billion in 2024 to $150 billion by 2035, without needing to directly unseat leaders Eli Lilly and Novo Nordisk. Beyond this specific deal, Pfizer's broader fundamentals show signs of improvement. The company reported a 10% year-over-year revenue increase to $14.7 billion and a 30% rise in adjusted EPS to $0.78 in the second quarter, supported by cost-saving initiatives and contributions from new products like its RSV vaccine Abrysvo, which generated $143 million. The investment thesis is further supported by a deep pipeline of over 100 programs and a compellingly low valuation, with the stock trading at 7.7 times forward earnings, significantly below the healthcare industry average of 16.5.

Key Decisions for Investors

• Given the combination of improving financial results, a diverse pipeline, and a forward P/E of 7.7x—less than half the industry average—investors may find Pfizer's current valuation an attractive entry point for a long-term position.
• The success of the $4.9 billion Metsera acquisition is contingent on clinical outcomes; therefore, investors should closely monitor trial data for key candidates like MET-097i, as positive results would serve as a major de-risking catalyst.
• Evaluate Pfizer's performance based on its entire diversified business, including the trajectory of recent launches like Abrysvo and progress across its 100+ program pipeline, not solely on its prospects in the GLP-1 market.